These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20498929)

  • 21. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF; Buchanan WW
    Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders.
    Stöllberger C; Finsterer J
    Z Kardiol; 2003 Sep; 92(9):721-9. PubMed ID: 14508588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs.
    Mitchell JA; Warner TD
    Nat Rev Drug Discov; 2006 Jan; 5(1):75-86. PubMed ID: 16485347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
    Nurmohamed MT; van Halm VP; Dijkmans BA
    Drugs; 2002; 62(11):1599-609. PubMed ID: 12109923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COX-2 inhibitors and the kidney.
    Appel GB
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S37-40. PubMed ID: 11695250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
    Konstantinopoulos PA; Lehmann DF
    J Clin Pharmacol; 2005 Jul; 45(7):742-50. PubMed ID: 15951464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.
    Patrono C
    Curr Cardiol Rep; 2016 Mar; 18(3):25. PubMed ID: 26841787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
    Prescrire Int; 2016 Jan; 25(167):14-6. PubMed ID: 26942254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global safety of coxibs and NSAIDs.
    Pham K; Hirschberg R
    Curr Top Med Chem; 2005; 5(5):465-73. PubMed ID: 15974941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction.
    Schjerning Olsen AM; Gislason GH; McGettigan P; Fosbøl E; Sørensen R; Hansen ML; Køber L; Torp-Pedersen C; Lamberts M
    JAMA; 2015 Feb; 313(8):805-14. PubMed ID: 25710657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.
    Abraham NS; El-Serag HB; Hartman C; Richardson P; Deswal A
    Aliment Pharmacol Ther; 2007 Apr; 25(8):913-24. PubMed ID: 17402995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP; Gertler R; Fricker R
    Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Toxicity of Cyclooxygenase Inhibitors and Promising Natur a l Substitutes.
    Bahmani M; Sarrafchi A; Shirzad H; Asgari S; Rafieian-Kopaei M
    Curr Pharm Des; 2017; 23(6):952-960. PubMed ID: 27719647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NSAIDs and cardiovascular risk.
    Marsico F; Paolillo S; Filardi PP
    J Cardiovasc Med (Hagerstown); 2017 Jan; 18 Suppl 1: Special Issue on The State of the Art for the Practicing Cardiologist: The 2016 Conoscere E Curare Il Cuore (CCC) Proceedings from the CLI Foundation():e40-e43. PubMed ID: 27652819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA
    Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.